Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-12-05
2006-12-05
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C536S023100, C435S320100, C435S091410, C930S010000, C424S199100
Reexamination Certificate
active
07144579
ABSTRACT:
The present invention provides virus vectors of the family Paramyxoviridae in which the transcription start (S) sequence has been modified so as to modify the expression of genes located downstream thereof, a method for producing the vectors, and uses thereof. By measuring the transcription initiation efficiency of the S sequence of each gene carried by Sendai viruses (SeV), it was clarified that the S sequence of F gene has a significantly lower ability to promote transcription than the other three S sequences. When the S sequence of the F gene of wild type Sendai virus was substituted by the S sequence of the P/M/HN gene-type showing a high transcription initiation efficiency, the F gene of the resultant Sendai virus mutant and genes located downstream thereof show elevated expression levels. It was also revealed that this mutant proliferates more quickly than the wild type. The vectors of this invention are useful in elevating the expression of foreign genes and producing pharmaceutical compositions and vaccines. Furthermore, by lowering virus gene expression from virus vectors, it is possible to suppress transcription and/or replication and reduce cytotoxicity of the vector genome.
REFERENCES:
patent: 5993824 (1999-11-01), Murphy et al.
patent: 6645760 (2003-11-01), Nagai et al.
patent: 6723532 (2004-04-01), Nagai et al.
patent: 6746860 (2004-06-01), Tokusumi et al.
patent: 6828138 (2004-12-01), Nagai et al.
patent: 2002/0002143 (2002-01-01), Kano et al.
patent: 2002/0098576 (2002-07-01), Nagai et al.
patent: 2003/0166252 (2003-09-01), Kitazato et al.
patent: 2003/0170210 (2003-09-01), Masaki et al.
patent: 2003/0170266 (2003-09-01), Kitazato et al.
patent: 2003/0170897 (2003-09-01), Imai et al.
patent: 2003/0203489 (2003-10-01), Yonemitsu et al.
patent: 2004/0005296 (2004-01-01), Yonemitsu et al.
patent: 2004/0053877 (2004-03-01), Fukumura et al.
patent: 2004/0101965 (2004-05-01), Griesenbach et al.
patent: 0 864 645 (1998-09-01), None
patent: 0863202 (1998-09-01), None
patent: WO 97/16538 (1997-09-01), None
Kato et al. Journal of Virology. Nov. 1999; 73 (11): 9237-9246.
Kuo et al. Journal of Virology. 1997; 71 (7): 4944-4953.
Hoffman and Banerjee, “Precise Mapping of the Replication and Transcription Promoters of Human Parainfluenza Virus Type 3,”Virology269:201-211 (2000).
Kato et al., “Sendai Virus Gene Start Signals Are Not Equivalent in Reinitiation Capacity: Moderation at the Fusion Protein Gene,”J. Virol., 73:9237-9246 (1999).
Stokes et al., “The Complete Nucleotide Sequence of Two Cold-Adapted, Temperature-Sensitive Attenuated Mutant Vaccine Viruses (cp12 and cp45) Derived from the JS Strain of Human Parainfluenza Virus Type 3 (PIV3),”Virus Research30:43-52 (1993).
Nagai et al., U.S. Appl. No. 09/132,521, filed Aug. 11, 1998.
Nagai et al., U.S. Appl. No. 09/471,840, filed Dec. 23, 1999.
Tokusumi et al., U.S. Appl. No. 09/702,498, filed Oct. 31, 2000.
Nagai et al., U.S. Appl. No. 09/728,207, filed Dec. 1, 2000.
Kano, et al., U.S. Appl. No. 09/823,699, filed Mar. 30, 2001.
Yonemitsu et al., U.S. Appl. No. 10/111,356, filed Jul. 30, 2002.
Masaki et al., U.S. Appl. No. 10/181,646, filed Nov. 22, 2002.
Yonemitsu et al., U.S. Appl. No. 10/306,949, filed Nov. 29, 2002.
Imai et al., U.S. Appl. No. 10/312,476, filed Apr. 10, 2003.
Kitazato et al., U.S. Appl. No. 10/316,535, filed Dec. 10, 2002.
Kitazato et al., U.S. Appl. No. 10/316,538, filed Dec. 10, 2002.
Fukumura et al., U.S. Appl. No. 10/398,598, filed Apr. 3, 2003.
Griesenbach et al., U.S. Appl. No. 10/416,252, filed May 8, 2003.
Yonemitsu et al., U.S. Appl. No. 10/444,661, filed May 23, 2003.
Conzelmann, “Nonsegmented Negative-Strand RNA Viruses: Genetics and Manipulation of Viral Genomes,”Ann. Rev. Genet., 32: 123-162 (1998).
Hasan et al., “Creation of an Inectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3′ Proximal First Locus,”J. of General Virology, 78: 2813-2820 (1997).
Kuo et al., “Effect of Mutations in the Gene-Start and Gene-End Sequence Motifs on Transcription of Monocistronic and Dicistronic Minigenomes of Respiratory Syncytial Virus,”J. of Virology, 70(10): 6892-6901 (1996).
Kuo et al., “Analysis of the Gene Start and Gene End Signals of Human Respiratory Syncytial Virus: Quasi-Templated Initiation at Position 1 of the Encoded mRNA,”J. of Virology, 71(7): 4944-4953 (1997).
Rassa and Parks, “Molecular Basis for Naturally Occurring Elevated Readthrough Transcription Across the M-F Junction of the Paramyxovirus SV5,”Virology247: 274-286 (1998).
Stillman and Whitt, “Mutational Analyses of the Intergenic Dinucleotide and the Transcriptional Start Sequence of Vesicular Stomatitis Virus (VSV) Define Sequences Required for Efficient Termination and Initiation of VSV Transcripts,”J. of Virology, 71(3): 2127-2137 (1997).
Nagai et al., U.S. Appl. No. 09/471,840, filed Dec. 23, 1999.
Nagai et al., U.S. Appl. No. 09/728,207, filed Dec. 1, 2000.
Kano, et al., U.S. Appl. No. 09/823,699, filed Mar. 30, 2001.
Masaki et al., U.S. Appl. No. 10/181,646, filed Nov. 22, 2002.
Yonemitsu et al., U.S. Appl. No. 10/306,949; filed Nov. 29, 2002.
Imai et al., U.S. Appl. No. 10/312,476, filed Apr. 10, 2003.
Kitazato et al., U.S. Appl. No. 10/316,535, filed Dec. 10, 2002.
Kitazato et al., U.S. Appl. No. 10/316,538, field Dec. 10, 2002.
Yonemitsu et al., U.S. Appl. No. 10/444,661, filed May 23, 2003.
Conzelmann, “Nonsegmented Negative-Strand RNA Viruses: Genetics and Manipulation of Viral Genomes,”Ann. Rev. Genet., 32: 123-162 (1998).
Hasan et al., “Creation of an Inectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3′ Proximal First Locus,”J. of General Virology, 78: 2813-2820 (1997).
Kuo et al., “Effect of Mutations in the Gene-Start and Gene-End Sequence Motifs on Transcription of Monocistronic and Dicistronic Minigenomes of Respiratory Syncytial Virus,”J. of Virology, 70(10): 6892-6901 (1996).
Kuo et al., “Analysis of the Gene Start and Gene End Signals of Human Respiratory Syncytial Virus: Quasi-Templated Initiation at Position 1 of the Encoded mRNA,”J. of Virology, 71(7): 4944-4953 (1997).
Rassa and Parks, “Molecular Basis for Naturally Occurring Elevated Readthrough Transcription Across the M-F Junction of the Paramyxovirus SV5,”Virology247: 274-286 (1998).
Stillman and Whitt, “Mutational Analyses of the Intergenic Dinucleotide and the Transcriptional Start Sequence of Vesicular Stomatitis Virus (VSV) Define Sequences Required for Efficient Termination and Initiation of VSV Transcripts,”J. of Virology, 71(3): 2127-2137 (1997).
Hasegawa Mamoru
Inoue Makoto
Kato Atsushi
Nagai Yoshiyuki
Blumel Benjamin P.
Campell Bruce R.
Clark & Elbing LLP
DNAVEC Research Inc.
LandOfFree
Paramyxoviruses comprising modified transcription start... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Paramyxoviruses comprising modified transcription start..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paramyxoviruses comprising modified transcription start... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3707702